Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.8%

52 terminated/withdrawn out of 407 trials

Success Rate

81.7%

-4.9% vs industry average

Late-Stage Pipeline

24%

98 trials in Phase 3/4

Results Transparency

24%

55 of 232 completed trials have results

Key Signals

29 recruiting55 with results48 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

152(44.6%)

Phase 3

63(18.5%)

N/A

52(15.2%)

Phase 1

36(10.6%)

Phase 4

35(10.3%)

Early Phase 1

3(0.9%)

341Total

Phase 2(152)

Phase 3(63)

N/A(52)

Phase 1(36)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (407)

Showing 20 of 407 trials

NCT04245085Phase 2Completed

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Role: collaborator

NCT03915678Phase 2Active Not Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Role: collaborator

NCT06225505Not ApplicableRecruiting

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

Role: collaborator

NCT05911178Not ApplicableActive Not Recruiting

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Role: collaborator

NCT04487756Phase 1Completed

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Role: collaborator

NCT07670117Not ApplicableNot Yet Recruiting

HAIQU (Hospital AIr QUality)

Role: collaborator

NCT04661358Phase 3Active Not Recruiting

Fenofibrate for Prevention of DR Worsening

Role: collaborator

NCT04161248Early Phase 1Active Not Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT05825625Phase 2Active Not Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Role: collaborator

NCT05525858Recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Role: collaborator

NCT01596790Not ApplicableCompleted

COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT01350882Phase 3Completed

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

Role: collaborator

NCT04984811Phase 2Terminated

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Role: collaborator

NCT05765084Phase 1Recruiting

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Role: collaborator

NCT03275311Recruiting

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Role: collaborator

NCT03848052Recruiting

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Role: collaborator

NCT05008081Recruiting

The CATALINA Study

Role: collaborator

NCT01208896Phase 2Completed

Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma

Role: collaborator

NCT02308527Phase 2Completed

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Role: collaborator

NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator